The Top 5 Biosimilars Articles for the Week of April 27

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 27, 2020.

Number 5: Biosimilar pricing is not as simple as a manufacturer's stated discount to the reference product cost, according to Adam Brufsky, MD, PhD, FACP, of the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.

Number 4: Taking an abundance of time to file a motion to block Kanjinti from coming to market, Genentech unwittingly may have tipped the scales in favor of biosimilar applicants.

Number 3: With a growing portfolio of biosimilars, Novartis saw a 31% increase in biopharmaceutical income for the first quarter of 2020, despite the pandemic.

Number 2: Samsung Bioepis isn't flinching on its trastuzumab biosimilar launch schedule, COVID-19 and 4 other biosimilar competitors notwithstanding, said Sang-Jin Pak, MD, executive vice president of the company's Commercial Division.

Number 1: Although the coronavirus disease 2019 (COVID-19) pandemic has put a burden on the economy and the healthcare system in particular, Kashyap Patel, MD, believes that the crisis will likely speed up biosimilar uptake in the United States.

To read all of these articles and more, visit centerforbiosimilars.com.